Linked Life Data

17511827

Source:http://linkedlifedata.com/resource/pubmed/id/17511827

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2007-8-13
pubmed:abstractText
We studied the main clinical features, outcome, and laboratory parameters in a group of solid organ transplant (SOT) patients with immunohistochemically proven cytomegalovirus (CMV) disease. Confirmed CMV cases were obtained through databases. Demographics, clinical data, transplantation type, immunosuppressive regimens, donor and recipient CMV serostatus, therapy, outcome and laboratory results, pp65 antigenemia, and qualitative polymerase chain reaction (PCR) for CMV were analyzed. From 1995 to 2004, 31 cases with complete medical records were identified. Disease appeared between 24 and 2538 days after transplantation but most cases presented in the first 100 days. Gastrointestinal CMV disease was the most frequent form (71%), while thrombocytopenia was present in 50% of cases, and leukopenia was less common (35.5%). CMV pp65 antigenemia was positive in 58% of patients, but its sensitivity increased to 71% if performed during the first 6 months. A qualitative CMV PCR technique gave similar results during this period (71.4%). Most patients were treated with intravenous ganciclovir (n=25; 80.6%). In 4 cases (19.4%), use of foscarnet alone or a sequential regimen with ganciclovir-foscarnet was deemed necessary. Surgical procedures were necessary in 5 patients (16%). The death rate reached 13%. CMV end-organ disease can be a life-threatening infection in SOT patients. Gastrointestinal disease was the most frequent end-organ disease. CMV antigen detection is best suited for the early period after transplantation.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1398-2273
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
203-10
pubmed:meshHeading
pubmed-meshheading:17511827-Adult, pubmed-meshheading:17511827-Aged, pubmed-meshheading:17511827-Antiviral Agents, pubmed-meshheading:17511827-Cytomegalovirus, pubmed-meshheading:17511827-Cytomegalovirus Infections, pubmed-meshheading:17511827-DNA, Viral, pubmed-meshheading:17511827-Disease Progression, pubmed-meshheading:17511827-Female, pubmed-meshheading:17511827-Foscarnet, pubmed-meshheading:17511827-Ganciclovir, pubmed-meshheading:17511827-Gastrointestinal Diseases, pubmed-meshheading:17511827-Humans, pubmed-meshheading:17511827-Immunohistochemistry, pubmed-meshheading:17511827-Male, pubmed-meshheading:17511827-Middle Aged, pubmed-meshheading:17511827-Phosphoproteins, pubmed-meshheading:17511827-Polymerase Chain Reaction, pubmed-meshheading:17511827-Transplantation, pubmed-meshheading:17511827-Viral Matrix Proteins
pubmed:year
2007
pubmed:articleTitle
Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests.
pubmed:affiliation
Infectious Diseases Service, Hospital Clinic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't